To include your compound in the COVID-19 Resource Center, submit it here.

Avonex interferon beta-1a autoimmune data

Researchers at the University of Rochester and colleagues published an analysis of the cost-effectiveness of DMTs to treat MS in the U.S. showing that use of DMTs for 10 years leads to modest health gains compared to best supportive care but at an incremental cost effectiveness ratio (ICER) that exceeded $800,000 per quality-adjusted life year (QALY). The researchers estimated that based on

Read the full 625 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers